{"name":"Precipio Diagnostics","slug":"precipio","ticker":"PRPO","exchange":"NASDAQ","domain":"precipiodx.com","description":"Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.","hq":"New Haven, CT","founded":0,"employees":"61","ceo":"Ilan Danieli","sector":"Molecular Diagnostics / Oncology","stockPrice":28.95,"stockChange":0.25,"stockChangePercent":0.87,"marketCap":"$52M","metrics":{"revenue":24049000,"revenueGrowth":22.9,"grossMargin":44.5,"rdSpend":1600000,"netIncome":-363000,"cash":2651000,"dividendYield":0,"peRatio":74.2,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-22","type":"earnings","headline":"Precipio Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Precipio Diagnostics reported its fourth quarter and full year 2022 financial results, with revenue of $1.4 million and a net loss of $2.3 million.","drugName":"","sentiment":"neutral"},{"date":"2022-06-15","type":"deal","headline":"Precipio Diagnostics Announces Partnership with Cancer Treatment Centers of America","summary":"Precipio Diagnostics announced a partnership with Cancer Treatment Centers of America to offer its OncoCEE test to patients.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPVEN1ZEstbnJTYUFxbEVNT0VyTXF5a29PYWdQUWliNFJ0VXBoVVo3ZFZxeDRQZk9xYWxPZHJaNG9NZVVNNERJYy1pMGlpX25CVGhKSEtyWHQwTEdtbjdDODAzVElqS2V1amhQN00yQWx1MVkxMm5WRm15LTR4eVNjWnZaaGZBVzJfejlPMzNTclFjMlF3Z0dCY0U1ZmdXeWJW?oc=5","date":"2026-03-30","type":"earnings","source":"Stock Titan","summary":"Precipio (NASDAQ: PRPO) 2025 annual report shows going-concern warning and revenue concentration - Stock Titan","headline":"Precipio (NASDAQ: PRPO) 2025 annual report shows going-concern warning and revenue concentration","sentiment":"neutral"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNVElUbDUzbTNjYjRxcEdXMTdUWm9fa3ZwRXRtLVhHSHo5OGgxcEphUlB1N2s4QktKRlJoSlEwS2xBcG1qS0hBTXRNMF9Jc29NSXk1SEV4VU1nZHJLSnlvWTIxUXZLQ2xSOHl4Y245VGpsQXQwR3JnZkJHckNHTzlCRFpIcVpMeUpuR3NGNHJKTDZtYm8xTHhYaDY3clA4MG1PNHJjTzR3VQ?oc=5","date":"2026-01-15","type":"pipeline","source":"Stock Titan","summary":"Cancer diagnostics firm erases $1.1M advance, keeps only small loan - Stock Titan","headline":"Cancer diagnostics firm erases $1.1M advance, keeps only small loan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQYzVuWVFCdUxpY25DdWRuTTU4RUpqWE55X21yX2kxeHo4UjRhdFg1UFAxZ1JXSHRTVnpFMmpIMHYwR0lEVTVIb19DeDNnaFFpYU0tQkNzVm5nbFRvYWhYaVVaeFl4QVczUlh0eHJxLVdVYmwtRnE2aFlvQTU0dVZFdGdXUWgyQ0wzLWtoNjFydjZNMFZmVm4tWTRneDFWSXZkUjRhQVhPVllrUFlYdWtlbzY3SGNDUW11NjB2Wg?oc=5","date":"2025-08-13","type":"earnings","source":"GlobeNewswire","summary":"Precipio Announces its Q2-2025 Financial Results - GlobeNewswire","headline":"Precipio Announces its Q2-2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE01d2RBQWVDSkJkeTBsRG1WT1BVY2xDaEpGM2cwV2I3SmUtRmNGOHFaUGR1NGYtbkswbzN4UVcwYzRja05Scmg2dVc3enpsd09lYkE?oc=5","date":"2017-07-12","type":"pipeline","source":"Yahoo Finance UK","summary":"Precipio, Inc. (PRPO) stock price, news, quote and history - Yahoo Finance UK","headline":"Precipio, Inc. (PRPO) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFBWYnduQ29Vd0dSRHd5T2h2clAzNUlvYkNDVjdTenlFQl9VeDh2MEZ6MmdaV21kUUNXQUJ4Y1M5OWh2RW93MWVETkFqTnlxUkREcFE?oc=5","date":"2017-07-11","type":"pipeline","source":"Yahoo Finance Australia","summary":"Precipio, Inc. (PRPO) stock price, news, quote and history - Yahoo Finance Australia","headline":"Precipio, Inc. (PRPO) stock price, news, quote and history","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Exact Sciences","Invitae","Foundation Medicine"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":24049000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":24049000,"period":"2025-12-31"},{"value":18532000,"period":"2024-12-31"},{"value":15197000,"period":"2023-12-31"},{"value":9412000,"period":"2022-12-31"},{"value":8849000,"period":"2021-12-31"},{"value":6092000,"period":"2020-12-31"}],"grossProfit":10706000,"grossProfitHistory":[{"period":"2025-12-31","value":10706000},{"period":"2024-12-31","value":7559000},{"period":"2023-12-31","value":6018000},{"period":"2022-12-31","value":2510000}],"rdSpend":1600000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-363000,"netIncomeHistory":[{"period":"2025-12-31","value":-363000},{"period":"2024-12-31","value":-4290000},{"period":"2023-12-31","value":-5853000},{"period":"2022-12-31","value":-12203000}],"eps":-0.23,"epsHistory":[{"period":"2025-12-31","value":-0.23},{"period":"2024-12-31","value":-2.93},{"period":"2023-12-31","value":-4.51},{"period":"2022-12-31","value":-10.73}],"cash":2651000,"cashHistory":[{"period":"2025-12-31","value":2651000},{"period":"2024-12-31","value":1389000},{"period":"2023-12-31","value":1502000},{"period":"2022-12-31","value":3445000}],"totalAssets":21317000,"totalLiabilities":6756000,"totalDebt":3653000,"equity":14561000,"operatingCashflow":685000,"operatingCashflowHistory":[{"period":"2025-12-31","value":685000},{"period":"2024-12-31","value":439000},{"period":"2023-12-31","value":-3559000},{"period":"2022-12-31","value":-7721000}],"capex":-326000,"capexHistory":[{"period":"2025-12-31","value":-326000},{"period":"2024-12-31","value":-223000},{"period":"2023-12-31","value":-126000},{"period":"2022-12-31","value":-277000}],"freeCashflow":359000,"dividendsPaid":null,"buybacks":null,"employees":61,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":542000,"ebitda":1018000,"period":"2025-12-31","revenue":6699000,"epsBasic":null,"netIncome":526000,"rdExpense":null,"epsDiluted":null,"grossProfit":3132000,"operatingIncome":542000},{"sga":null,"ebit":-70000,"ebitda":367000,"period":"2025-09-30","revenue":6767000,"epsBasic":-0.05,"netIncome":-79000,"rdExpense":null,"epsDiluted":-0.05,"grossProfit":3005000,"operatingIncome":-61000},{"sga":-789000,"ebit":97000,"ebitda":519000,"period":"2025-06-30","revenue":5654000,"epsBasic":0.05,"netIncome":74000,"rdExpense":null,"epsDiluted":0.05,"grossProfit":2429000,"operatingIncome":-824000},{"sga":null,"ebit":-859000,"ebitda":-442000,"period":"2025-03-31","revenue":4929000,"epsBasic":-0.59,"netIncome":-884000,"rdExpense":null,"epsDiluted":-0.59,"grossProfit":2140000,"operatingIncome":-859000},{"sga":null,"ebit":-336000,"ebitda":46000,"period":"2024-12-31","revenue":5450000,"epsBasic":null,"netIncome":-365000,"rdExpense":null,"epsDiluted":null,"grossProfit":2646000,"operatingIncome":-336000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.42,"netIncome":null,"rdExpense":null,"epsDiluted":-0.42,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":28.95,"previousClose":28.7,"fiftyTwoWeekHigh":33.63,"fiftyTwoWeekLow":7.05,"fiftyTwoWeekRange":"7.05 - 33.63","fiftyDayAverage":27.98,"twoHundredDayAverage":22.48,"beta":1.38,"enterpriseValue":52193672,"forwardPE":74.2,"priceToBook":3.54,"priceToSales":2.15,"enterpriseToRevenue":2.17,"enterpriseToEbitda":225.95,"pegRatio":0,"ebitda":231000,"ebitdaMargin":1,"freeCashflow":210125,"operatingCashflow":685000,"totalDebt":3653000,"debtToEquity":25.1,"currentRatio":1.61,"returnOnAssets":-3.9,"returnOnEquity":-2.7,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":11.9,"institutionHeldPercent":17.7,"sharesOutstanding":1784830,"floatShares":1422255,"sharesShort":7078,"shortRatio":0.2,"shortPercentOfFloat":0.4,"epsTrailing":-0.23,"epsForward":0.39,"revenuePerShare":14.98,"bookValue":8.18,"officers":[{"age":53,"name":"Mr. Ilan  Danieli","title":"Founder, President, CEO & Director"},{"age":40,"name":"Mr. Ahmed Zaki Sabet","title":"Chief Operating Officer"},{"age":41,"name":"Dr. Ayman A. Mohamed M.D.","title":"Chief Technology Officer"},{"age":58,"name":"Mr. Matthew  Gage","title":"Chief Financial Officer"},{"age":null,"name":"Ms. Miri  Chiko-Radomski","title":"Chief Legal Counsel & People Officer"}],"industry":"Diagnostics & Research","irWebsite":"http://www.transgenomic.com/ir/Shareholder.asp","website":"https://www.precipiodx.com","phone":"203 787 7888"}}